Active Biotech wins Japan patent for laquinimod eye-drop formulation through 2042
Bitget2026/09/30 09:02- Active Biotech secured a Japan patent for an ophthalmic laquinimod formulation, strengthening its intellectual property position in a key pharmaceutical market.
- The grant provides potential market exclusivity in Japan until 2042 under patent number 7,918,190.
- The eye-drop formulation targets delivery to the back of the eye for severe inflammatory diseases, including non-infectious uveitis.
- Management aims to move laquinimod into Phase II uveitis trials with a commercial partner; partnering discussions are ongoing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
24 Hour Crypto Recap: Here’s What Happened in the Market
AI investment is reshaping the bond market! Sunak: By 2027, the net issuance of long-term bonds by technology companies may surpass that of the US government
By 2027, tech companies are expected to become larger net issuers of long-term debt than the U.S. government.
Crypto prices
More
